Alasdair M Barr

Summary

Affiliation: University of British Columbia
Country: Canada

Publications

  1. ncbi Selective effects of typical antipsychotic drugs on SNAP-25 and synaptophysin in the hippocampal trisynaptic pathway
    Alasdair M Barr
    Center for Complex Disorders, Department of Psychiatry, University of British Columbia, Vancouver General Hospital Research Pavilion, 828 West 10th Avenue, Vancouver, BC, Canada
    Int J Neuropsychopharmacol 9:457-63. 2006
  2. ncbi A longitudinal study on the effects of typical versus atypical antipsychotic drugs on hippocampal volume in schizophrenia
    William J Panenka
    Department of Psychiatry, University of British Columbia, 828 West 10th Ave, Vancouver, BC, Canada, V5Z 1L8
    Schizophr Res 94:288-92. 2007
  3. pmc A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy
    William G Honer
    BC Mental Health and Addictions Research Institute, University of British Columbia, Vancouver, BC, Canada
    J Psychiatry Neurosci 34:433-42. 2009
  4. pmc Pharmacological risk factors for delirium after cardiac surgery: a review
    Lurdes Tse
    Department of Anesthesiology, Pharmacology and Therapeutics, The University of British Columbia, 2176 Health Sciences Mall, Vancouver, B C, Canada, V6T 1Z3
    Curr Neuropharmacol 10:181-96. 2012
  5. pmc Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine
    Heidi N Boyda
    Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada
    PLoS ONE 8:e53459. 2013
  6. pmc Methamphetamine-associated psychosis: a new health challenge in Iran
    Zahra Alam Mehrjerdi
    Iranian National Center for Addiction Studies INCAS, Tehran University of Medical Sciences, NO, 669, South Karegar Ave, Tehran, Iran
    Daru 21:30. 2013
  7. doi Self-reported motivation to smoke in schizophrenia is related to antipsychotic drug treatment
    Alasdair M Barr
    Faculty of Medicine, Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada
    Schizophr Res 100:252-60. 2008
  8. ncbi Prenatal ethanol exposure in rats decreases levels of complexin proteins in the frontal cortex
    Alasdair M Barr
    Center for Complex Disorders, Department of Psychiatry, University of British Columbia, Vancouver General Hospital Research Pavilion, Vancouver, Canada
    Alcohol Clin Exp Res 29:1915-20. 2005
  9. ncbi A novel, systemically active, selective galanin receptor type-3 ligand exhibits antidepressant-like activity in preclinical tests
    Alasdair M Barr
    Department of Molecular and Integrative Neurosciences, The Scripps Research Institute, La Jolla, CA, United States
    Neurosci Lett 405:111-5. 2006
  10. pmc The need for speed: an update on methamphetamine addiction
    Alasdair M Barr
    Centre for Complex Disorders, Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada
    J Psychiatry Neurosci 31:301-13. 2006

Detail Information

Publications55

  1. ncbi Selective effects of typical antipsychotic drugs on SNAP-25 and synaptophysin in the hippocampal trisynaptic pathway
    Alasdair M Barr
    Center for Complex Disorders, Department of Psychiatry, University of British Columbia, Vancouver General Hospital Research Pavilion, 828 West 10th Avenue, Vancouver, BC, Canada
    Int J Neuropsychopharmacol 9:457-63. 2006
    ..These results indicate that presynaptic proteins represent a potential molecular substrate for the effects of antipsychotic drugs on hippocampal synaptic connectivity...
  2. ncbi A longitudinal study on the effects of typical versus atypical antipsychotic drugs on hippocampal volume in schizophrenia
    William J Panenka
    Department of Psychiatry, University of British Columbia, 828 West 10th Ave, Vancouver, BC, Canada, V5Z 1L8
    Schizophr Res 94:288-92. 2007
    ..This longitudinal study measured changes in symptoms and hippocampal volume in patients switched from typical antipsychotics to olanzapine...
  3. pmc A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy
    William G Honer
    BC Mental Health and Addictions Research Institute, University of British Columbia, Vancouver, BC, Canada
    J Psychiatry Neurosci 34:433-42. 2009
    ..Better linkage between the components of translational research may improve the appropriate use of medications such as clozapine in psychiatric practice...
  4. pmc Pharmacological risk factors for delirium after cardiac surgery: a review
    Lurdes Tse
    Department of Anesthesiology, Pharmacology and Therapeutics, The University of British Columbia, 2176 Health Sciences Mall, Vancouver, B C, Canada, V6T 1Z3
    Curr Neuropharmacol 10:181-96. 2012
    ..The objective of this review is to evaluate the literature on medications associated with delirium after cardiac surgery and potential prophylactic agents for preventing it...
  5. pmc Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine
    Heidi N Boyda
    Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada
    PLoS ONE 8:e53459. 2013
    ..We therefore used preclinical models to evaluate the metabolic side-effects of glucose intolerance and insulin resistance with the novel SGAs asenapine and iloperidone for the first time. Olanzapine was used as a comparator...
  6. pmc Methamphetamine-associated psychosis: a new health challenge in Iran
    Zahra Alam Mehrjerdi
    Iranian National Center for Addiction Studies INCAS, Tehran University of Medical Sciences, NO, 669, South Karegar Ave, Tehran, Iran
    Daru 21:30. 2013
    ..It is hoped that special training courses are designed and implemented by health policy makers to inform clinicians, health providers and especially emergency medicine specialists to effectively deal with MAP...
  7. doi Self-reported motivation to smoke in schizophrenia is related to antipsychotic drug treatment
    Alasdair M Barr
    Faculty of Medicine, Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada
    Schizophr Res 100:252-60. 2008
    ..While a number of theories have been proposed to account for such high rates of smoking, little is known about the subjective motivation for why schizophrenia patients smoke in comparison with those without the disease...
  8. ncbi Prenatal ethanol exposure in rats decreases levels of complexin proteins in the frontal cortex
    Alasdair M Barr
    Center for Complex Disorders, Department of Psychiatry, University of British Columbia, Vancouver General Hospital Research Pavilion, Vancouver, Canada
    Alcohol Clin Exp Res 29:1915-20. 2005
    ....
  9. ncbi A novel, systemically active, selective galanin receptor type-3 ligand exhibits antidepressant-like activity in preclinical tests
    Alasdair M Barr
    Department of Molecular and Integrative Neurosciences, The Scripps Research Institute, La Jolla, CA, United States
    Neurosci Lett 405:111-5. 2006
    ..These combined data from two species indicate that GalR3 receptor antagonists may exhibit antidepressant-like effects...
  10. pmc The need for speed: an update on methamphetamine addiction
    Alasdair M Barr
    Centre for Complex Disorders, Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada
    J Psychiatry Neurosci 31:301-13. 2006
    ..It is hoped that increased knowledge of MA abuse will provide the basis for future treatment strategies...
  11. ncbi Heterozygous reeler mice exhibit alterations in sensorimotor gating but not presynaptic proteins
    Alasdair M Barr
    Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada V6T 1Z3
    Eur J Neurosci 27:2568-74. 2008
    ..However, it is unlikely that these behavioral differences may be accounted for by altered regional levels of presynaptic proteins...
  12. ncbi A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model
    Heidi N Boyda
    Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Vancouver, BC, Canada V6T 1Z3
    Prog Neuropsychopharmacol Biol Psychiatry 34:945-54. 2010
    ..Together, these findings indicate that acute administration of antipsychotic drugs has potent effects on metabolic regulation of glucose and insulin sensitivities, which may contribute to metabolic side-effects seen in humans...
  13. ncbi Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats
    Alasdair M Barr
    Molecular and Integrative Neurosciences Department, The Scripps Research Institute, La Jolla, CA, USA
    Neuropharmacology 51:457-65. 2006
    ..The absence of effect in isolation-reared rats may be due to the relatively small effect size of isolation rearing on PPI or dose of iloperidone...
  14. doi Antipsychotic polypharmacy increases metabolic dysregulation in female rats
    Heidi N Boyda
    Department of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Vancouver, B C, Canada, V6T 1Z3
    Exp Clin Psychopharmacol 21:164-71. 2013
    ..Future studies related to understanding the physiological mechanisms involved remain a priority...
  15. pmc The reelin receptors VLDLR and ApoER2 regulate sensorimotor gating in mice
    Alasdair M Barr
    Department of Psychiatry, University of British Columbia, Vancouver, B C, Canada
    Neuropharmacology 52:1114-23. 2007
    ..These findings have relevance to a range of neuropsychiatric disorders that involve sensorimotor gating deficits, including schizophrenia...
  16. ncbi Altered performance of reelin-receptor ApoER2 deficient mice on spatial tasks using the Barnes maze
    Alasdair M Barr
    Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada
    Behav Neurosci 121:1101-5. 2007
    ..ApoER2 knockout mice also displayed altered use of specific search strategies and relationship of these strategies to errors made on the maze...
  17. doi Role of estradiol withdrawal in 'anhedonic' sucrose consumption: a model of postpartum depression
    Amanda D Green
    Department of Psychology, Neuroscience Program and Brain Research Centre, The University of British Columbia, Vancouver, Canada
    Physiol Behav 97:259-65. 2009
    ..Together, these results suggest an important, though complex, role for gonadal hormones in the behavioral changes accompanying this model of depression...
  18. doi Effects of sub-chronic clozapine and haloperidol administration on brain lipid levels
    Vilte E Barakauskas
    Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada
    Prog Neuropsychopharmacol Biol Psychiatry 34:669-73. 2010
    ..Our findings suggest that observed alterations in brain lipid profiles in individuals with schizophrenia are not a consequence of treatment with antipsychotic medications...
  19. pmc Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats
    Heidi N Boyda
    Department of Anesthesiology and Pharmacology, University of British Columbia, Vancouver, BC
    J Psychiatry Neurosci 37:407-15. 2012
    ..However, use of the drug is commonly associated with a range of metabolic side effects, including glucose intolerance and insulin resistance. These symptoms have been accurately modelled in rodents...
  20. doi Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients
    Ric M Procyshyn
    British Columbia Mental Health and Addictions Research Institute, A3 113, 938 W 28th Ave, Vancouver, British Columbia, Canada, V5Z 4H4
    J Clin Psychiatry 71:566-73. 2010
    ....
  21. ncbi Increased expression of glial fibrillary acidic protein in prefrontal cortex in psychotic illness
    Abigail H Feresten
    Department of Psychiatry, University of British Columbia, Vancouver, Canada
    Schizophr Res 150:252-7. 2013
    ..Lack of ALDH1L1 and vimentin variability and increased GFAP levels may imply that astrocyte numbers are unchanged but astrocytes are partially activated, or may indicate a specific dysregulation of GFAP...
  22. doi Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings
    William J Panenka
    Department of Psychiatry, University of British Columbia, Vancouver, Canada
    Drug Alcohol Depend 129:167-79. 2013
    ..Treatment options include pharmacological, psychological or combination therapies. The present review summarizes the key findings in the literature spanning from molecular through to clinical effects...
  23. pmc Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment
    Ric M Procyshyn
    Department of Research, Riverview Hospital, Port Coquitlam, BC, Canada
    J Psychiatry Neurosci 32:331-8. 2007
    ..The primary objective of this study was to determine whether an increase in serum lipids is associated with improvement in schizophrenia symptoms during steady state treatment with clozapine...
  24. ncbi Predictors of starting to smoke cigarettes in patients with first episode psychosis
    Geoffrey N Smith
    University of British Columbia, Vancouver, Canada
    Schizophr Res 108:258-64. 2009
    ..However, genetic, obstetric and early life conditions are risks for starting to smoke in the general population but their role in psychotic patients is unclear...
  25. pmc A novel mechanism and treatment target for presynaptic abnormalities in specific striatal regions in schizophrenia
    Vilte E Barakauskas
    Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada
    Neuropsychopharmacology 35:1226-38. 2010
    ..SNARE proteins and their interactions may be a novel target for the development of therapeutics...
  26. ncbi Psychostimulant withdrawal as an inducing condition in animal models of depression
    Alasdair M Barr
    Department of Neuropharmacology, CVN 7, The Scripps Research Institute, 10550 North Torrey Pines Rd, La Jolla, CA 92037 USA
    Neurosci Biobehav Rev 29:675-706. 2005
    ..Recent progress and limitations in the development of this model, as well as future directions for research, are evaluated and discussed...
  27. doi Predictors of persistent psychotic symptoms in persons with methamphetamine abuse receiving psychiatric treatment
    Tania Lecomte
    Departement de Psychologie, Universite de Montreal, Montreal, Quebec, Canada Center for Psychiatric Rehabilitation, Boston University, Massachusetts Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada Department of Psychology, and Faculty of Health Sciences, University of Simon Fraser, Burnaby, British Columbia, Canada Department of Radiology, University of British Columbia, Vancouver, British Columbia, Canada and Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada
    J Nerv Ment Dis 201:1085-9. 2013
    ..This study also highlights the importance of identifying people with persistent psychosis within MA users to facilitate rapid and effective treatment of co-occurring psychotic disorder. ..
  28. ncbi Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia
    William G Honer
    Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada
    CNS Drugs 21:699-714. 2007
    ..Trials need to be designed to investigate widely used approaches such as antipsychotic polypharmacy, where actual practice diverges from evidence-based guidelines...
  29. ncbi Electroconvulsive shock treatment differentially modulates cortical and subcortical endocannabinoid activity
    Matthew N Hill
    Department of Psychology, University of British Columbia, Vancouver, British Columbia, Canada
    J Neurochem 103:47-56. 2007
    ....
  30. ncbi Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease
    Jeremy M Van Raamsdonk
    Department of Medical Genetics and Centre for Molecular Medicine and Therapeutics, British Columbia Research Institute for Children s and Women s Health, University of British Columbia, 980 West 28th Avenue, Vancouver, BC, Canada V5Z 4H4
    Exp Neurol 196:266-72. 2005
    ..Overall, this work demonstrates the feasibility of experimental therapeutics in the YAC128 mouse model and suggests that experiments in these mice may be predictive for future human clinical trials...
  31. ncbi Abnormalities of presynaptic protein CDCrel-1 in striatum of rats reared in social isolation: relevance to neural connectivity in schizophrenia
    Alasdair M Barr
    Centre for Complex Disorders, University of British Columbia, 828 West 10th Avenue, Vancouver, BC, Canada V5Z 1L8
    Eur J Neurosci 20:303-7. 2004
    ....
  32. pmc Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests
    Tamas Bartfai
    Department of Neuropharmacology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 101:10470-5. 2004
    ..These data further implicate brain and spinal cord galanin receptors as drug targets and provide an example of a systemically active compound based on a scaffold that mimics protein surfaces...
  33. doi Preclinical models of antipsychotic drug-induced metabolic side effects
    Heidi N Boyda
    Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Vancouver, B C, Canada, V6T 1Z3
    Trends Pharmacol Sci 31:484-97. 2010
    ..In this paper, we provide a major review of this important and growing field of preclinical study, and address crucial issues for future research...
  34. doi Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system
    Joanne Y T Leung
    Department of Pharmacology, University of British Columbia, 2176 Health Sciences Mall, Vancouver, B C V6T1Z3, Canada
    Pharmacol Ther 135:113-22. 2012
    ..The direct and indirect effects of antipsychotic drugs on the cardiovascular system and their possible mechanisms of action are discussed in this review, where both preclinical and clinical findings are integrated...
  35. pmc Personalized risk assessment of drug-related harm is associated with health outcomes
    Andrea A Jones
    Department of Psychiatry, University of British Columbia, Vancouver, Canada
    PLoS ONE 8:e79754. 2013
    ..We hypothesized that a personalized, ISCD-based Composite Harm Score (CHS) would be associated with poor health outcomes in polysubstance users...
  36. ncbi A 'crash' course on psychostimulant withdrawal as a model of depression
    Alasdair M Barr
    Associate Professor, Dept of Neuropharmacology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Trends Pharmacol Sci 23:475-82. 2002
    ..Current advances and limitations in the development of this model, together with recent evidence that psychostimulant withdrawal in rodents can be used to screen for novel, rapidly acting antidepressant treatments, are discussed...
  37. doi Medication errors in psychiatry: a comprehensive review
    Ric M Procyshyn
    British Columbia Mental Health and Addictions Services Research Institute, Vancouver, British Columbia, Canada
    CNS Drugs 24:595-609. 2010
    ..Medication errors in psychiatry have been studied almost exclusively in the inpatient setting and thus little is known about the incidence and significance in outpatient and community settings...
  38. ncbi Repeated electroconvulsive shock attenuates the depressive-like effects of d-amphetamine withdrawal on brain reward function in rats
    Alasdair M Barr
    Department of Psychology, University of British Columbia, Vancouver, Canada
    Psychopharmacology (Berl) 159:196-202. 2002
    ..One of the more prominent symptoms is a loss of hedonic capacity; in animals, the anhedonia associated with amphetamine withdrawal has been measured objectively by decrements in responding for intracranial self-stimulation (ICSS)...
  39. ncbi Exposure to repeated, intermittent d-amphetamine induces sensitization of HPA axis to a subsequent stressor
    Alasdair M Barr
    Department of Psychology, 2136 West Mall, University of British Columbia, Vancouver, BC, Canada V6T 1Z4
    Neuropsychopharmacology 26:286-94. 2002
    ....
  40. pmc A role for galanin in antidepressant actions with a focus on the dorsal raphe nucleus
    Xiaoying Lu
    Department of Neuropharmacology and The Harold L Dorris Neurological Research Center, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 102:874-9. 2005
    ....
  41. pmc A retrospective study of antipsychotic drug switching in a pediatric population
    David Linton
    British Columbia Mental Health and Addictions Services Research Institute, 938 W 28th Avenue, Vancouver, BC V5Z 4H4, Canada
    BMC Psychiatry 13:248. 2013
    ..Drug switching may occur through a limited number of established patterns. The nature of these changes is not well characterized in youth, despite their frequent occurrence...
  42. doi Smoking cessation interventions among individuals in methadone maintenance: a brief review
    Chizimuzo T C Okoli
    British Columbia Centre of Excellence for Women s Health, Box 48, Vancouver, British Columbia, Canada V6H 3N1
    J Subst Abuse Treat 38:191-9. 2010
    ....
  43. ncbi Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension
    Lurdes Tse
    Departments of aAnesthesiology, Pharmacology and Therapeutics bPsychiatry, University of British Columbia cBC Mental Health and Addictions Research Institute, Vancouver, British Columbia, Canada
    Int Clin Psychopharmacol 29:125-37. 2014
    ..The literature on adjunct medications for the treatment of antipsychotic-associated dyslipidemia and hypertension is not exhaustive, and long-term randomized-controlled trials would offer valuable results. ..
  44. doi Prevalence and patterns of antipsychotic use in youth at the time of admission and discharge from an inpatient psychiatric facility
    Ric M Procyshyn
    From the British Columbia Mental Health and Addictions Research Institute Departments of Psychiatry, and Anesthesiology, Pharmacology and Therapeutics, University of British Columbia Child and Adolescent Mental Health Inpatient Units, and Department of Pharmacy, British Columbia Children s Hospital, Vancouver, British Columbia, Canada
    J Clin Psychopharmacol 34:17-22. 2014
    ..Whether the significant increase in antipsychotic use seen from the time of admission to discharge is solely attributed to clinical worsening or other variables requires further investigation. ..
  45. doi Antidiabetic-drug combination treatment for glucose intolerance in adult female rats treated acutely with olanzapine
    Heidi N Boyda
    Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada
    Prog Neuropsychopharmacol Biol Psychiatry 48:170-6. 2014
    ..These findings indicate that further study of antidiabetic dual-drug combinations in patients treated with antipsychotic drugs is warranted. ..
  46. doi Antipsychotic and psychostimulant drug combination therapy in attention deficit/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability
    David Linton
    British Columbia Mental Health and Addictions Research Institute, A3 938 W 28th Avenue, Vancouver, B C V5Z 4H4, Canada
    Curr Psychiatry Rep 15:355. 2013
    ..Further studies are necessary to confirm the efficacy and tolerability of the concurrent use of antipsychotics and psychostimulants in children and adolescents...
  47. doi Effect of hypertriglyceridemia on the pharmacokinetics and blood-brain barrier penetration of clozapine and norclozapine following administration to rats
    Pavel Gershkovich
    Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada
    Eur Neuropsychopharmacol 20:545-52. 2010
    ..Taken together, the results do not support the hypothesis that hypertriglyceridemia improves the effect of clozapine by altered pharmacokinetics of clozapine and norclozapine and their increased penetration across the BBB...
  48. ncbi The selective serotonin-2A receptor antagonist M100907 reverses behavioral deficits in dopamine transporter knockout mice
    Alasdair M Barr
    Department of Neuropharmacology, The Scripps Research Institute, La Jolla, CA, USA
    Neuropsychopharmacology 29:221-8. 2004
    ....
  49. ncbi Clozapine administered once versus twice daily: does it make a difference?
    Ric M Procyshyn
    British Columbia Mental Health and Addictions Research Institute, 938 W 28th Avenue, Vancouver, B C V5Z 4H4, Canada Department of Psychiatry, University of British Columbia, Vancouver V6T 1Z3, Canada Electronic address
    Med Hypotheses 82:225-8. 2014
    ..We present here some pharmacokinetic simulations and published data to support our hypothesis. ..
  50. ncbi Determination of clozapine and its metabolite, norclozapine in various biological matrices using high-performance liquid chromatography
    Micheal Rosland
    Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada
    Drug Dev Ind Pharm 33:1158-66. 2007
    ..To develop and validate an HPLC method for the quantitation of clozapine and its metabolite, norclozapine in human plasma, rat plasma, and the various human plasma lipoprotein fractions...
  51. ncbi Role of integrin-linked kinase in nerve growth factor-stimulated neurite outgrowth
    Julia Mills
    Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, Canada V6T 123
    J Neurosci 23:1638-48. 2003
    ..Consequently, ILK inhibition resulted in an increase in the hyperphosphorylation of Tau, a substrate of GSK-3. Together these findings indicate that ILK is an important effector in NGF-mediated neurite outgrowth...
  52. ncbi Increased successive negative contrast in rats withdrawn from an escalating-dose schedule of D-amphetamine
    Alasdair M Barr
    Department of Psychology, University of British Columbia, Vancouver, British Columbia, Canada
    Pharmacol Biochem Behav 71:293-9. 2002
    ..This effect is interpreted as a consequence of the increased emotionality of withdrawn animals, and may be related to disruption of normal search behaviors...
  53. ncbi High levels of estradiol impair spatial performance in the Morris water maze and increase 'depressive-like' behaviors in the female meadow vole
    Liisa A M Galea
    Department of Psychology and Neuroscience Program, The University of British Columbia, Vancouver, British Columbia, Canada
    Physiol Behav 77:217-25. 2002
    ..To our knowledge, this is the first demonstration in rodents indicating that estradiol-mediated changes in behavior in the FST is not indicative of subsequent performance in the Morris water maze...
  54. ncbi High frequency of TNF alleles -238A and -376A in individuals from northern Sardinia
    Sebastian A Wirz
    The Harold L Dorris Neurological Research Center, Department of Neuropharmacology, The Scripps Research Institute, 10550 North Torrey Pines Road, SR307, La Jolla, CA 92037, USA
    Cytokine 26:149-54. 2004
    ....
  55. ncbi Hippocampal complexin proteins and cognitive dysfunction in schizophrenia
    Ken Sawada
    Department of Neuropsychiatry, Kochi Medical School, Kochi, Japan
    Arch Gen Psychiatry 62:263-72. 2005
    ..A putative molecular mechanism implicates abnormalities of proteins involved in the presynaptic secretory machinery, including the modulator proteins complexin I and complexin II...